Shield Therapeutics plc (LSE:STX) has delivered its strongest quarterly performance to date, with net revenues reaching $13.1 million and a 15% increase in prescriptions for its flagship product ACCRUFeR compared to the previous quarter.
The company credits this momentum to targeted marketing strategies and a focused sales push, which have accelerated product uptake. Shield remains on course to achieve cash flow breakeven by the end of 2025—an important operational milestone in its growth trajectory.
While strong technical performance reflects solid market momentum, the company continues to face financial challenges, including negative profitability and cash flow constraints. Valuation pressures, such as a negative P/E ratio and the absence of a dividend, also weigh on investor sentiment.
About Shield Therapeutics plc
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on treating iron deficiency with its innovative oral therapy ACCRUFeR® (also marketed as FeRACCRU®). The product is distributed in the U.S. through a partnership with Viatris, with additional licensing agreements covering Europe, China, Japan, and other international markets.
Leave a Reply